Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ME NASDAQ:TELO NASDAQ:UNCY NASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsTELOTelomir Pharmaceuticals$1.56-6.6%$1.72$1.12▼$8.40$46.43M-0.679.27 million shs513,610 shsUNCYUnicycive Therapeutics$4.09+0.7%$5.53$2.02▼$11.00$51.70M1.88432,081 shs225,053 shsVRCAVerrica Pharmaceuticals$6.35+3.9%$6.59$3.82▼$58.20$58.73M1.9244,052 shs10,701 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceME23andMe0.00%0.00%0.00%0.00%-93.35%TELOTelomir Pharmaceuticals0.00%-11.36%+33.33%-37.35%-60.80%UNCYUnicycive Therapeutics0.00%-2.62%-22.10%-25.64%+17.66%VRCAVerrica Pharmaceuticals0.00%+12.59%-27.22%+44.32%-87.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationME23andMeN/AN/AN/AN/AN/AN/AN/AN/ATELOTelomir Pharmaceuticals3.2108 of 5 stars3.84.00.00.02.20.00.6UNCYUnicycive Therapeutics2.6806 of 5 stars3.72.00.00.02.91.70.6VRCAVerrica Pharmaceuticals4.1181 of 5 stars3.12.00.04.73.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceME23andMe 0.00N/AN/AN/ATELOTelomir Pharmaceuticals 3.50Strong Buy$15.00861.54% UpsideUNCYUnicycive Therapeutics 3.33Buy$60.001,366.99% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$80.001,159.84% UpsideCurrent Analyst Ratings BreakdownLatest ME, UNCY, TELO, and VRCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$90.005/14/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/AUNCYUnicycive Therapeutics$680K76.03N/AN/A$0.72 per share5.68VRCAVerrica Pharmaceuticals$7.57M7.76N/AN/A($1.07) per share-5.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)UNCYUnicycive Therapeutics-$36.73M-$5.10N/AN/AN/AN/A-277.30%-61.53%N/AVRCAVerrica Pharmaceuticals-$76.58M-$12.00N/AN/AN/AN/AN/A-145.63%8/12/2025 (Estimated)Latest ME, UNCY, TELO, and VRCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025N/ATELOTelomir Pharmaceuticals-$0.08N/AN/AN/AN/AN/A8/12/2025Q2 2025VRCAVerrica Pharmaceuticals-$0.10N/AN/AN/A$4.37 millionN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$1.40-$0.50+$0.90-$0.05N/AN/A5/13/2025Q1 2025VRCAVerrica Pharmaceuticals-$1.40-$1.00+$0.40-$0.10$2.53 million$3.44 million5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthME23andMeN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioME23andMeN/A1.050.91TELOTelomir PharmaceuticalsN/A0.750.75UNCYUnicycive TherapeuticsN/A1.641.64VRCAVerrica PharmaceuticalsN/A1.341.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipME23andMe36.10%TELOTelomir PharmaceuticalsN/AUNCYUnicycive Therapeutics40.42%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipME23andMe26.32%TELOTelomir PharmaceuticalsN/AUNCYUnicycive Therapeutics10.71%VRCAVerrica Pharmaceuticals54.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableME23andMe77026.83 million19.77 millionNot OptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/AUNCYUnicycive Therapeutics912.64 million11.29 millionNot OptionableVRCAVerrica Pharmaceuticals409.25 million4.26 millionOptionableME, UNCY, TELO, and VRCA HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on WednesdayAugust 7 at 5:36 AM | marketbeat.comVerrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025August 6, 2025 | globenewswire.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from BrokeragesAugust 5, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?August 3, 2025 | marketbeat.comShort Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%August 2, 2025 | marketbeat.comVerrica Pharmaceuticals Implements Reverse Stock SplitAugust 1, 2025 | theglobeandmail.comVerrica Pharmaceuticals (NASDAQ:VRCA) Shares Gap Down - What's Next?July 26, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...July 12, 2025 | finance.yahoo.comVerrica Pharmaceuticals Inc News (VRCA) - Investing.comJuly 11, 2025 | investing.comVerrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed ...July 11, 2025 | seekingalpha.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by AnalystsJuly 11, 2025 | marketbeat.comVerrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% - Should You Sell?July 10, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025July 9, 2025 | globenewswire.comVerrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsJuly 1, 2025 | globenewswire.comVerrica Shareholder Sues Board Over FDA Approval Hurdle ClaimsJune 27, 2025 | news.bloomberglaw.comNVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 28, 2025 | globenewswire.comVerrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in PipelineMay 18, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference CallMay 13, 2025 | seekingalpha.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comVerrica Pharmaceuticals Reports Quarterly 2025 Financial ResultsMay 13, 2025 | globenewswire.com6VRCA : Earnings Outlook For Verrica PharmaceuticalsMay 13, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation America Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?3 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025View 3 Stocks Riding the AI Data Center Buildout WaveSuper Micro Computer Sees Unusual Volume—Catalyst Ahead?By Gabriel Osorio-Mazilli | July 25, 2025View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?Why Wall Street Is Betting on These 3 Comeback StocksBy Nathan Reiff | July 12, 2025View Why Wall Street Is Betting on These 3 Comeback StocksME, UNCY, TELO, and VRCA Company Descriptions23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.Telomir Pharmaceuticals NASDAQ:TELO$1.56 -0.11 (-6.59%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.59 +0.03 (+1.92%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Unicycive Therapeutics NASDAQ:UNCY$4.09 +0.03 (+0.74%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.13 +0.04 (+0.98%) As of 08/8/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.Verrica Pharmaceuticals NASDAQ:VRCA$6.35 +0.24 (+3.93%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.34 0.00 (-0.08%) As of 08/8/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
